Blaise Pasquiers presents the mAbs project at PhinC

Since the first market placement of a monoclonal antibody (mAb) in 1986, more and more treatments from this category of therapeutics have taken their place on the market. At PhinC Development – as a member of MabDesign – we support sponsors throughout their monoclonal antibodies development process.

Read full article below  ⇓ ⇓

French Tech Paris-Saclay
Club Phase 1
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI
MabDesign